TY - JOUR
T1 - Association between chronic kidney disease and COVID-19-related mortality in New York
AU - Mohamed, Nihal E.
AU - Benn, Emma K.T.
AU - Astha, Varuna
AU - Okhawere, Kennedy E.
AU - Korn, Talia G.
AU - Nkemdirim, William
AU - Rambhia, Ami
AU - Ige, Olajumoke A.
AU - Funchess, Hassan
AU - Mihalopoulos, Meredith
AU - Meilika, Kirolos N.
AU - Kyprianou, Natasha
AU - Badani, Ketan K.
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
PY - 2021/8
Y1 - 2021/8
N2 - Purpose: To evaluate mortality risk of CKD patients infected with COVID-19, and assess shared characteristics associated with health disparities in CKD outcome. Methods: We extracted the data from a case series of 7624 patients presented at Mount Sinai Health System, in New York for testing between 3/28/2020 and 4/16/2020. De-identified patient data set is being produced by the Scientific Computing department and made available to the Mount Sinai research community at the following website: https://msdw.mountsinai.org/. Results: Of 7624 COVID-19 patients, 7.8% (n = 597) had CKD on hospital admission, and 11.2% (n = 856) died of COVID-19 infection. CKD patients were older, more likely to have diabetes, hypertension, and chronic obstructive pulmonary disease (COPD), were current or former smokers, had a longer time to discharge, and had worse survival compared to non-CKD patients (p < 0.05). COVID-19 mortality rate was significantly higher in CKD patients (23.1% vs 10.2%) with a 1.51 greater odds of dying (95% CI: 1.19–1.90). Controlling for demographic, behavioral, and clinical covariates, the logistic regression analysis showed significant and consistent effects of CKD, older age, male gender, and hypertension with mortality (p < 0.05). Conclusion: CKD was a significant independent predictor of COVID-19 mortality, along with older age, male gender, and hypertension. Future research will investigate the effects of COVID-19 on long-term renal function.
AB - Purpose: To evaluate mortality risk of CKD patients infected with COVID-19, and assess shared characteristics associated with health disparities in CKD outcome. Methods: We extracted the data from a case series of 7624 patients presented at Mount Sinai Health System, in New York for testing between 3/28/2020 and 4/16/2020. De-identified patient data set is being produced by the Scientific Computing department and made available to the Mount Sinai research community at the following website: https://msdw.mountsinai.org/. Results: Of 7624 COVID-19 patients, 7.8% (n = 597) had CKD on hospital admission, and 11.2% (n = 856) died of COVID-19 infection. CKD patients were older, more likely to have diabetes, hypertension, and chronic obstructive pulmonary disease (COPD), were current or former smokers, had a longer time to discharge, and had worse survival compared to non-CKD patients (p < 0.05). COVID-19 mortality rate was significantly higher in CKD patients (23.1% vs 10.2%) with a 1.51 greater odds of dying (95% CI: 1.19–1.90). Controlling for demographic, behavioral, and clinical covariates, the logistic regression analysis showed significant and consistent effects of CKD, older age, male gender, and hypertension with mortality (p < 0.05). Conclusion: CKD was a significant independent predictor of COVID-19 mortality, along with older age, male gender, and hypertension. Future research will investigate the effects of COVID-19 on long-term renal function.
KW - COVID-19
KW - Chronic kidney disease
KW - Comorbidity
KW - Mortality
KW - Pandemic
KW - Virus
UR - http://www.scopus.com/inward/record.url?scp=85099753812&partnerID=8YFLogxK
U2 - 10.1007/s00345-020-03567-4
DO - 10.1007/s00345-020-03567-4
M3 - Article
C2 - 33481113
AN - SCOPUS:85099753812
SN - 0724-4983
VL - 39
SP - 2987
EP - 2993
JO - World Journal of Urology
JF - World Journal of Urology
IS - 8
ER -